The DOI matches its Crossref record; 182 of the 182 references it cites were found in a registry or an index.
Principles in the design of ligand-targeted cancer therapeutics and imaging agents
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,612
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., & Jain, R. K. (1995) · PubMed · Cited by 1,711
Openings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
van Dam, G. M., Themelis, G., Crane, L. M. A., Harlaar, N. J., Pleijhuis, R. G., Kelder, W., Sarantopoulos, A., de Jong, J. S., Arts, H. J. G., van der Zee, A. G. J., et al. (2011) · Nature Medicine · doi:10.1038/nm.2472 · Cited by 1,545
Self-citationMucins in cancer: function, prognosis and therapy
Kufe, D. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2761 · Cited by 1,396
Gabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
Overall, C. M., & Kleifeld, O. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1821 · Cited by 1,214
Parker, N., Turk, M. J., Westrick, E., Lewis, J. D., Low, P. S., & Leamon, C. P. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2004.12.026 · Cited by 1,197
Self-citationAntibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307628 · Cited by 930
Cell Surface Polarity in Epithelia
Simons, K., & Fuller, S. D. (1985) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.01.110185.001331 · Cited by 876
Structure of the δ-opioid receptor bound to naltrindole
Granier, S., Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Weis, W. I., & Kobilka, B. K. (2012) · Nature · doi:10.1038/nature11111 · Cited by 667
Kupffer cells are central in the removal of nanoparticles from the organism
Sadauskas, E., Wallin, H., Stoltenberg, M., Vogel, U., Doering, P., Larsen, A., & Danscher, G. (2007) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-4-10 · Cited by 607
Delivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies
Chauhan, V. P., Stylianopoulos, T., Boucher, Y., & Jain, R. K. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114300 · Cited by 597
Liu, Y., Cao, Y., Zhang, W., Bergmeier, S., Qian, Y., Akbar, H., Colvin, R., Ding, J., Tong, L., Wu, S., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0131 · Cited by 555
Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis.
Leamon, C. P., & Low, P. S. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.13.5572 · Cited by 554
Self-citationThe tumour microenvironment in B cell lymphomas
Scott, D. W., & Gascoyne, R. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3774 · Cited by 552
Seshadri, R., Firgaira, F. A., Horsfall, D. J., McCaul, K., Setlur, V, & Kitchen, P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1936 · Cited by 528
Yoo, J.-W., Chambers, E., & Mitragotri, S. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791920496 · Cited by 521
Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1
Seltzer, M. J., Bennett, B. D., Joshi, A. D., Gao, P., Thomas, A. G., Ferraris, D. V., Tsukamoto, T., Rojas, C. J., Slusher, B. S., Rabinowitz, J. D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1666 · Cited by 513
Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
Montagut, C., Sharma, S. V., Shioda, T., McDermott, U., Ulman, M., Ulkus, L. E., Dias-Santagata, D., Stubbs, H., Lee, D. Y., Singh, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6787 · Cited by 508
Targeted therapy using nanotechnology: focus on cancer
Sechi, M., Sanna, V., & Pala, N. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s36654 · Cited by 493
Folate receptor alpha as a tumor target in epithelial ovarian cancer
Kalli, K. R., Oberg, A. L., Keeney, G. L., Christianson, T. J. H., Low, P. S., Knutson, K. L., & Hartmann, L. C. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.11.020 · Cited by 475
Self-citationHuang, J., Bu, L., Xie, J., Chen, K., Cheng, Z., Li, X., & Chen, X. (2010) · ACS Nano · doi:10.1021/nn101643u · Cited by 463
Manzoor, A. A., Lindner, L. H., Landon, C. D., Park, J.-Y., Simnick, A. J., Dreher, M. R., Das, S., Hanna, G., Park, W., Chilkoti, A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1683 · Cited by 459
Folate-targeted therapies for cancer
Xia, W., & Low, P. S. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100509v · Cited by 448
Self-citationReceptor-targeted nanocarriers for therapeutic delivery to cancer
Yu, B., Tai, H. C., Xue, W., Lee, L. J., & Lee, R. J. (2010) · Molecular Membrane Biology · doi:10.3109/09687688.2010.521200 · Cited by 423
Kim, H., Lee, D., Kim, J., Kim, T.-I., & Kim, W. J. (2013) · ACS Nano · doi:10.1021/nn403096s · Cited by 420
Juweid, M. E., Neumann, R. D., Paik, C. H., Pérez-Bacete, M., Sato, J., van Osdol, W. W., & Weinstein, J. N. (1992) · PubMed · Cited by 406
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
van der Meel, R., Vehmeijer, L. J. C., Kok, R. J., Storm, G., & van Gaal, E. V. B. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.012 · Cited by 398
Chen, Y., Pullambhatla, M., Foss, C. A., Byun, Y., Nimmagadda, S., Senthamizhchelvan, S., Sgouros, G., Mease, R. C., & Pomper, M. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1357 · Cited by 388
Régina, A., Demeule, M., Ché, C., Lavallée, I., Poirier, J., Gabathuler, R., Béliveau, R., & Castaigne, J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.260 · Cited by 368
The proliferation rate paradox in antimitotic chemotherapy
Mitchison, T. J. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-04-0335 · Cited by 363
Zimmerman, E. S., Heibeck, T. H., Gill, A., Li, X., Murray, C. J., Madlansacay, M. R., Tran, C., Uter, N. T., Yin, G., Rivers, P. J., et al. (2014) · Bioconjugate Chemistry · doi:10.1021/bc400490z · Cited by 363
Brune, V., Tiacci, E., Pfeil, I., Döring, C., Eckerle, S., van Noesel, C. J. M., Klapper, W., Falini, B., von Heydebreck, A., Metzler, D., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080809 · Cited by 360
Chen, S., Zhao, X., Chen, J., Chen, J., Kuznetsova, L., Wong, S. S., & Ojima, I. (2010) · Bioconjugate Chemistry · doi:10.1021/bc9005656 · Cited by 357
Lee, H., Fonge, H., Hoang, B., Reilly, R. M., & Allen, C. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100038h · Cited by 349
Schmalfeldt, B., Prechtel, D., Härting, K., Späthe, K., Rutke, S., Konik, E., Fridman, R., Berger, U., Schmitt, M., Kuhn, W. C., et al. (2001) · PubMed · Cited by 334
Controlled targeting of liposomal doxorubicin via the folate receptor in vitro
Saul, J. M., Annapragada, A., Natarajan, J. V., & Bellamkonda, R. V. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00295-5 · Cited by 303
Nelson, C. E., Kintzing, J. R., Hanna, A., Shannon, J. M., Gupta, M. K., & Duvall, C. L. (2013) · ACS Nano · doi:10.1021/nn403325f · Cited by 293
In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry
He, W., Wang, H., Hartmann, L. C., Cheng, J.-X., & Low, P. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703875104 · Cited by 292
Self-citationCho, S. Y., Gage, K. L., Mease, R. C., Senthamizhchelvan, S., Holt, D. P., Jeffrey-Kwanisai, A., Endres, C. J., Dannals, R. F., Sgouros, G., Lodge, M., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.104661 · Cited by 279
Targeted drug delivery for cancer therapy: the other side of antibodies
Firer, M. A., & Gellerman, G. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-70 · Cited by 269
Hatakeyama, H., Ito, E., Akita, H., Oishi, M., Nagasaki, Y., Futaki, S., & Harashima, H. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.06.008 · Cited by 254
Targeting C-type lectin receptors with multivalent carbohydrate ligands
Lepenies, B., Lee, J., & Sonkaria, S. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.05.007 · Cited by 251
Peptides in cancer nanomedicine: Drug carriers, targeting ligands and protease substrates
Zhang, X.-X., Eden, H. S., & Chen, X. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.023 · Cited by 243
Engineering Folate–Drug Conjugates to Target Cancer: From Chemistry to Clinic
Vlahov, I. R., & Leamon, C. P. (2012) · Bioconjugate Chemistry · doi:10.1021/bc2005522 · Cited by 240
Naumann, R. W., Coleman, R. L., Burger, R. A., Sausville, E. A., Kutarska, E., Ghamande, S. A., Gabrail, N. Y., DePasquale, S. E., Nowara, E., Gilbert, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.7685 · Cited by 238
Tumor Targeting via Integrin Ligands
Marelli, U. K., Rechenmacher, F., Sobahi, T. R. A., Mas-Moruno, C., & Kessler, H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00222 · Cited by 236
Hillier, S. M., Maresca, K. P., Lu, G., Merkin, R. D., Marquis, J. C., Zimmerman, C. N., Eckelman, W. C., Joyal, J. L., & Babich, J. W. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.116624 · Cited by 230
Cao, X., Fang, L., Gibbs, S., Huang, Y., Dai, Z., Wen, P., Zheng, X., Sadee, W., & Sun, D. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0291-9 · Cited by 221
Paulos, C. M., Reddy, J. A., Leamon, C. P., Turk, M. J., & Low, P. S. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.003723 · Cited by 220
Self-citation68Ga-Labeled Inhibitors of Prostate-Specific Membrane Antigen (PSMA) for Imaging Prostate Cancer
Banerjee, S. R., Pullambhatla, M., Byun, Y., Nimmagadda, S., Green, G., Fox, J. J., Horti, A., Mease, R. C., & Pomper, M. G. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100623e · Cited by 213
Synthesis and Biological Evaluation of EC20: A New Folate-Derived, 99mTc-Based Radiopharmaceutical
Leamon, C. P., Parker, M. A., Vlahov, I. R., Xu, L.-C., Reddy, J. A., Vetzel, M., & Douglas, N. (2002) · Bioconjugate Chemistry · doi:10.1021/bc0200430 · Cited by 210
First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer
Barrett, J. A., Coleman, R. E., Goldsmith, S. J., Vallabhajosula, S., Petry, N. A., Cho, S., Armor, T., Stubbs, J. B., Maresca, K. P., Stabin, M. G., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.111203 · Cited by 208
Sigma-2 receptors as a biomarker of proliferation in solid tumours
Wheeler, K. T., Wang, L.-M., Wallen, C. A., Childers, S. R., Cline, J. M., Keng, P. C., & Mach, R. H. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1067 · Cited by 200
Auristatin Antibody Drug Conjugate Physical Instability and the Role of Drug Payload
Adem, Y. T., Schwarz, K. A., Duenas, E., Patapoff, T. W., Galush, W. J., & Esue, O. (2014) · Bioconjugate Chemistry · doi:10.1021/bc400439x · Cited by 194
Ojima, I. (2008) · Accounts of Chemical Research · doi:10.1021/ar700093f · Cited by 191
Kularatne, S. A., Wang, K., Santhapuram, H.-K. R., & Low, P. S. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900069d · Cited by 191
Self-citationGENT: Gene Expression Database of Normal and Tumor Tissues
Shin, G., Kang, T.-W., Yang, S., Baek, S.-J., Jeong, Y.-S., & Kim, S.-Y. (2011) · Cancer Informatics · doi:10.4137/cin.s7226 · Cited by 188
ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells
Chittasupho, C., Xie, S.-X., Baoum, A., Yakovleva, T., Siahaan, T. J., & Berkland, C. J. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.02.008 · Cited by 181
Methods for site-specific drug conjugation to antibodies
Behrens, C. R., & Liu, B. (2014) · mAbs · doi:10.4161/mabs.26632 · Cited by 171
Kularatne, S. A., Zhou, Z., Yang, J., Post, C. B., & Low, P. S. (2009) · Molecular Pharmaceutics · doi:10.1021/mp9000712 · Cited by 171
Self-citationvan Osdol, W. W., Fujimori, K., & Weinstein, J. N. (1991) · PubMed · Cited by 170
Kurzrock, R., Gabrail, N., Chandhasin, C., Moulder, S., Smith, C., Brenner, A., Sankhala, K., Mita, A., Elian, K., Bouchard, D., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0566 · Cited by 168
Osteoactivin Promotes Breast Cancer Metastasis to Bone
Rose, A. A. N., Pepin, F., Russo, C., Abou Khalil, J. E., Hallett, M., & Siegel, P. M. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0119 · Cited by 163
Sandström, M., Velikyan, I., Garske-Román, U., Sörensen, J., Eriksson, B., Granberg, D., Lundqvist, H., Sundin, A., & Lubberink, M. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.120600 · Cited by 161
Antibody–Drug Conjugate (ADC) Clinical Pipeline: A Review
Sassoon, I., & Blanc, V. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-541-5_1 · Cited by 157
Zhao, R., Min, S. H., Wang, Y., Puchulu‐Campanella, E., Low, P. S., & Goldman, I. D. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m807665200 · Cited by 155
Self-citationO'Shannessy, D. J., Somers, E. B., Maltzman, J. D., Smale, R., & Fu, Y. (2012) · SpringerPlus · doi:10.1186/2193-1801-1-22 · Cited by 155
He, W., Kularatne, S. A., Kalli, K. R., Prendergast, F. G., Amato, R. J., Klee, G. G., Hartmann, L. C., & Low, P. S. (2008) · International Journal of Cancer · doi:10.1002/ijc.23717 · Cited by 151
Self-citationEGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes
Grandal, M. V., Zandi, R., Pedersen, M. W., Willumsen, B. M., van Deurs, B., & Poulsen, H. S. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm058 · Cited by 151
Lang, L., Li, W., Guo, N., Ma, Y., Zhu, L., Kiesewetter, D. O., Shen, B., Niu, G., & Chen, X. S. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200197h · Cited by 148
Real-time monitoring of drug release
Weinstain, R., Segal, E., Satchi‐Fainaro, R., & Shabat, D. (2009) · Chemical Communications · doi:10.1039/b919329d · Cited by 144
Fisher, R. E., Siegel, B. A., Edell, S. L., Oyesiku, N. M., Morgenstern, D. E., Messmann, R. A., & Amato, R. J. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.049478 · Cited by 143
Eckerle, S., Brune, V., Döring, C., Tiacci, E., Bohle, V., Sundström, C., Kodet, R., Paulli, M., Falini, B., Klapper, W., et al. (2009) · Leukemia · doi:10.1038/leu.2009.161 · Cited by 137
Coloff, J. L., Macintyre, A. N., Nichols, A., Liu, T., Gallo, C. A., Plas, D. R., & Rathmell, J. C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4531 · Cited by 137
Kashiwagi, H., McDunn, J. E., Simon, P. O., Goedegebuure, P. S., Xu, J., Jones, L. A., Chang, K. C., Johnston, F. M., Trinkaus, K. M., Hotchkiss, R. S., et al. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-48 · Cited by 132
Binding and interstitial penetration of liposomes within avascular tumor spheroids
Kostarelos, K., Emfietzoglou, D., Papakostas, A., Yang, W., Ballangrud, Å., & Sgouros, G. (2004) · International Journal of Cancer · doi:10.1002/ijc.20457 · Cited by 127
Folate-modified gold nanoclusters as near-infrared fluorescent probes for tumor imaging and therapy
Chen, H., Li, S., Li, B., Ren, X., Li, S., Mahounga, D. M., Cui, S., Gu, Y., & Achilefu, S. A. (2012) · Nanoscale · doi:10.1039/c2nr31616a · Cited by 127
Targeted Drug Delivery and Penetration Into Solid Tumors
Corti, A., Pastorino, F., Curnis, F., Arap, W., Ponzoni, M., & Pasqualini, R. (2011) · Medicinal Research Reviews · doi:10.1002/med.20238 · Cited by 125
Battle, M. R., Goggi, J., Allen, L., Barnett, J., & Morrison, M. S. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.077479 · Cited by 121
Antibody–drug conjugates – a perfect synergy
Adair, J. R., Howard, P. W., Hartley, J. A., Williams, D. G., & Chester, K. A. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.693473 · Cited by 120
Shahied, L., Tang, Y., Alpaugh, R. K., Somer, R. A., Greenspon, D., & Weiner, L. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407888200 · Cited by 120
Yang, J. J. J., Chen, H., Vlahov, I. R., Cheng, J., & Low, P. S. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.117648 · Cited by 117
Self-citationWang, X., Ma, D., Olson, W. C., & Heston, W. D. W. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0191 · Cited by 116
Xiao, Y., Jaskula‐Sztul, R., Javadi, A., Xu, W., Eide, J. G., Dammalapati, A., Kunnimalaiyaan, M., Chen, H., & Gong, S. (2012) · Nanoscale · doi:10.1039/c2nr31853a · Cited by 114
Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA
Sakurai, Y., Hatakeyama, H., Sato, Y., Akita, H., Takayama, K., Kobayashi, S., Futaki, S., & Harashima, H. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.04.047 · Cited by 114
Roivainen, A., Kähkönen, E., Luoto, P., Borkowski, S., Hofmann, B., Jambor, I., Lehtiö, K., Rantala, T., Rottmann, A., Sipilä, H., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.114082 · Cited by 114
Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice
Shi, H., Li, D., Zhang, J., Wang, Y., Li, Y., Zhang, H., Wang, X., Mu, B., Wang, W., Ma, Y., et al. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01562.x · Cited by 114
Ivetac, A., & McCammon, J. A. (2010) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2010.01012.x · Cited by 113
Effect of Folate-Targeted Nanoparticle Size on Their Rates of Penetration into Solid Tumors
Vlashi, E., Kelderhouse, L. E., Sturgis, J. E., & Low, P. S. (2013) · ACS Nano · doi:10.1021/nn402644g · Cited by 110
Self-citationPreclinical Antitumor Activity of a Novel Folate-Targeted Dual Drug Conjugate
Leamon, C. P., Reddy, J. A., Vlahov, I. R., Westrick, E. M., Dawson, A., Dorton, R., Vetzel, M., Santhapuram, H. K. R., & Wang, Y. (2007) · Molecular Pharmaceutics · doi:10.1021/mp070049c · Cited by 109
Development of Tumor-Targeted Near Infrared Probes for Fluorescence Guided Surgery
Kelderhouse, L. E., Chelvam, V., Wayua, C., Mahalingam, S. M., Poh, S., Kularatne, S. A., & Low, P. S. (2013) · Bioconjugate Chemistry · doi:10.1021/bc400131a · Cited by 108
Self-citationWeinstein, J. N., & van Osdol, W. (1992) · PubMed · Cited by 104
Simpson, C. D., Mawji, I. A., Anyiwe, K., Williams, M. A., Wang, X., Venugopal, A. L., Gronda, M., Hurren, R., Cheng, S., Serra, S., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2530 · Cited by 104
Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer
Schröder, C., Witzel, I., Müller, V., Krenkel, S., Wirtz, R. M., Jänicke, F., Schumacher, U., & Milde‐Langosch, K. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-0984-2 · Cited by 103
Current Progress of Aptamer-Based Molecular Imaging
Wang, A. Z., & Farokhzad, O. C. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.126144 · Cited by 103
Zhang, J., Wu, J., Wang, X., Wang, J., Zhang, X., & Zhang, Q. (2010) · Molecular Pharmaceutics · doi:10.1021/mp1000235 · Cited by 101
Design and evaluation of new pH-sensitive amphiphilic cationic lipids for siRNA delivery
Malamas, A. S., Gujrati, M. D., Kummitha, C. M., Xu, R., & Lu, Z. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.06.019 · Cited by 100
Usami, Y., Ishida, K., Sato, S., Kishino, M., Kiryu, M., Ogawa, Y., Okura, M., Fukuda, Y., & Toyosawa, S. (2013) · International Journal of Cancer · doi:10.1002/ijc.28066 · Cited by 99
Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model
Guo, W., Zhang, Y., Chen, T., Wang, Y., Xue, J., Zhang, Y., Xiao, W., Mo, X., & Lü, Y. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0860-5 · Cited by 99
Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors
LoRusso, P. M., Edelman, M. J., Bever, S. L., Forman, K., Pilat, M., Quinn, M. F., Li, J., Heath, E. I., Malburg, L., Klein, P. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.4946 · Cited by 98
Liang, L., Lin, S., Dai, W., Lu, J., Yang, T., Xiang, Y., Zhang, Y., Li, R., & Zhang, Q. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.02.020 · Cited by 97
Recent advances in ligand targeted therapy
Trapani, G., Denora, N., Trapani, A., & Laquintana, V. (2011) · Journal of drug targeting · doi:10.3109/1061186x.2011.611518 · Cited by 97
Huo, M., Zou, A., Yao, C., Zhang, Y., Zhou, J., Wang, J., Zhu, Q., Li, J., & Zhang, Q. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.05.052 · Cited by 97
Miller, M. A., Meyer, A. S., Beste, M. T., Lasisi, Z., Reddy, S., Jeng, K., Chen, C., Han, J., Isaacson, K., Griffith, L. G., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222387110 · Cited by 96
Ciuleanu, T., Pavlovsky, A. V., Bodoky, G., Garin, A. M., Langmuir, V. K., Kroll, S., & Tidmarsh, G. F. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.12.022 · Cited by 91
Bispecific small molecule–antibody conjugate targeting prostate cancer
Kim, C. H., Axup, J. Y., Lawson, B. R., Yun, H., Tardif, V., Choi, S. H., Zhou, Q., Dubrovska, A., Biroc, S. L., Marsden, R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316026110 · Cited by 89
The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer
Crane, L. M. A., Arts, H. J. G., van Oosten, M., Low, P. S., van der Zee, A. G. J., van Dam, G. M., & Bart, J. (2011) · Cellular Oncology · doi:10.1007/s13402-011-0052-6 · Cited by 88
Self-citationIlluminating somatostatin analog action at neuroendocrine tumor receptors
Reubi, J. C., & Schönbrunn, A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.10.001 · Cited by 88
Nanoparticle therapeutics for prostate cancer treatment
Sanna, V., & Sechi, M. (2012) · Maturitas · doi:10.1016/j.maturitas.2012.01.016 · Cited by 88
Ligand‐Targeted Delivery of Small Interfering RNAs to Malignant Cells and Tissues
Thomas, M., Kularatne, S. A., Qi, L., Kleindl, P. J., Leamon, C. P., Hansen, M. J., & Low, P. S. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04977.x · Cited by 85
Self-citationNanoparticle therapeutics for prostate cancer treatment
Sanna, V., & Sechi, M. (2012) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2012.05.009 · Cited by 84
Multivalent Ligand: Design Principle for Targeted Therapeutic Delivery Approach
Chittasupho, C. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.99 · Cited by 82
Kinet, S., Swainson, L. A., Lavanya, M., Mongellaz, C., Montel‐Hagen, A., Craveiro, M., Manel, N., Battini, J., Sitbon, M., & Taylor, N. N. (2007) · Retrovirology · doi:10.1186/1742-4690-4-31 · Cited by 80
Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors
Roosenburg, S., Laverman, P., van Delft, F. L., & Boerman, O. C. (2010) · Amino Acids · doi:10.1007/s00726-010-0501-y · Cited by 78
Hornick, J. R., Xu, J., Vangveravong, S., Tu, Z., Mitchem, J. B., Spitzer, D., Goedegebuure, P. S., Mach, R. H., & Hawkins, W. G. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-298 · Cited by 78
Cagle, P. T., Zhai, Q. “., Murphy, L., & Low, P. S. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0176-oa · Cited by 77
Self-citationNuclear Receptor Expression Defines a Set of Prognostic Biomarkers for Lung Cancer
Jeong, Y., Xie, Y., Xiao, G., Behrens, C., Girard, L., Wistuba, I. I., Minna, J. D., & Mangelsdorf, D. J. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000378 · Cited by 76
Gao, H., Lang, L., Guo, N., Cao, F., Quan, Q., Hu, S., Kiesewetter, D. O., Niu, G., & Chen, X. S. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2052-1 · Cited by 73
Heterobivalent ligands target cell-surface receptor combinations in vivo
Xu, L., Josan, J. S., Vágner, J., Caplan, M. R., Hruby, V. J., Mash, E. A., Lynch, R. M., Morse, D. L., & Gillies, R. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211762109 · Cited by 73
Holbeck, S. L., Chang, J., Best, A. M., Bookout, A. L., Mangelsdorf, D. J., & Martinez, E. D. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0040 · Cited by 71
Folate–Vinca Alkaloid Conjugates for Cancer Therapy: A Structure–Activity Relationship
Leamon, C. P., Vlahov, I. R., Reddy, J. A., Vetzel, M., Santhapuram, H. K. R., You, F., Bloomfield, A., Dorton, R., Nelson, M., Kleindl, P. J., et al. (2014) · Bioconjugate Chemistry · doi:10.1021/bc400441s · Cited by 70
Maurer, A. H., Elsinga, P. H., Fanti, S., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.133074 · Cited by 70
Release of Soluble Urokinase Receptor from Vascular Cells*
Chavakis, T., Willuweit, A., Lupu, F., Preissner, K. T., & Kanse, S. M. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1616105 · Cited by 70
Inhibitory effects of oroxylin A on endothelial protein C receptor shedding in vitro and in vivo
Ku, S., Han, M. S., Lee, M. Y., Lee, Y. M., & Bae, J. (2014) · BMB Reports · doi:10.5483/bmbrep.2014.47.6.198 · Cited by 69
Assessment of Chemoselective Neoglycosylation Methods Using Chlorambucil as a Model
Goff, R. D., & Thorson, J. S. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101024j · Cited by 66
Targeting Folate Receptors to Treat Invasive Urinary Bladder Cancer
Dhawan, D., Ramos‐Vara, J. A., Naughton, J. F., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2101 · Cited by 65
Guiding Principles in The Design of Ligand-Targeted Nanomedicines
Wang, X., Galliford, C. V., & Low, P. S. (2014) · Nanomedicine · doi:10.2217/nnm.13.175 · Cited by 63
Self-citationJin, Y., Liu, Y., Lin, Q., Li, J., Druso, J. E., Antonyak, M. A., Meininger, C. J., Zhang, S. L., Dostal, D. E., Guan, J., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00650-13 · Cited by 61
Briasoulis, E. C., Judson, I. R., Pavlidis, N. A., Beale, P. J., Wanders, J., Groot, Y., Veerman, G., Schuessler, M., Niebch, G., Siamopoulos, K. C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3535 · Cited by 61
Guo, N., Lang, L., Li, W., Kiesewetter, D. O., Gao, H., Niu, G., Xie, Q., & Chen, X. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037506 · Cited by 60
McGuire, M. J., Gray, B. P., Li, S., Cupka, D., Byers, L. A., Wu, L., Rezaie, S., Liu, Y.-H., Pattisapu, N., Issac, J., et al. (2014) · Scientific Reports · doi:10.1038/srep04480 · Cited by 55
Shao, L., Liu, S., Hou, J., Yan-hua, Z., Peng, C., Zhong, Y.-J., Liu, X., Liu, X., Hong, Y., Firestone, R. A., et al. (2011) · Cancer · doi:10.1002/cncr.26596 · Cited by 54
Kigawa, J., Minagawa, Y., Kanamori, Y., Itamochi, H., Cheng, X., Okada, M., Oishi, T., & Terakawa, N. (1998) · Cancer · Cited by 54
Antibody–Drug Conjugate Target Selection: Critical Factors
Bander, N. H. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-541-5_2 · Cited by 54
Gpnmb/osteoactivin, an attractive target in cancer immunotherapy
Zhou, L., LIU, F. Y., Li, Y., Peng, Y., LIU, Y. H., & LI, J. (2011) · Neoplasma · doi:10.4149/neo_2012_001 · Cited by 52
Targeted chemotherapy for triple-negative breast cancers via LHRH receptor
Gründker, C. (2011) · Oncology Reports · doi:10.3892/or.2011.1188 · Cited by 52
Effect of Receptor Occupancy on Folate Receptor Internalization
Bandara, N. A., Hansen, M. J., & Low, P. S. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400659t · Cited by 52
Self-citationSpitzer, D., Simon, P. O., Kashiwagi, H., Xu, J., Zeng, C., Vangveravong, S., Zhou, D., Chang, K. C., McDunn, J. E., Hornick, J. R., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1354 · Cited by 51
Folate Receptor-β in Activated Macrophages: Ligand Binding and Receptor Recycling Kinetics
Varghese, B., Vlashi, E., Xia, W. G., Ayala-López, W., Paulos, C. M., Reddy, J. A., Xu, L., & Low, P. S. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500348e · Cited by 50
Self-citationWayua, C., & Low, P. S. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400429h · Cited by 49
Self-citationSakurai, Y., Hatakeyama, H., Akita, H., Oishi, M., Nagasaki, Y., Futaki, S., & Harashima, H. (2009) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.32.928 · Cited by 48
Leamon, C. P., Reddy, J. A., Klein, P., Vlahov, I. R., Dorton, R., Bloomfield, A., Nelson, M., Westrick, E. M., Parker, N. L., Bruna, K., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.175109 · Cited by 47
Liu, X., Guo, J., Han, S. J., Yao, L., Chen, A., Yang, Q., Bo, H., Xu, P., Yin, J., & Zhang, Z. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.08.054 · Cited by 46
(2013) · Methods in molecular biology · doi:10.1007/978-1-62703-541-5 · Cited by 46
Tsuji, T., Yoshitomi, H., & Usukura, J. (2012) · Microscopy · doi:10.1093/jmicro/dfs080 · Cited by 45
Quantitative Receptor-Based Imaging of Tumor Proliferation with the Sigma-2 Ligand [18F]ISO-1
Shoghi, K. I., Xu, J., Su, Y., He, J., Rowland, D., Yan, Y., Garbow, J. R., Tu, Z., Jones, L. A., Higashikubo, R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074188 · Cited by 44
Klinaki, I., AL-NAHHAS, A. M., Soneji, N. D. R., & Win, Z. (2013) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e31827a2325 · Cited by 44
Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV‐134
Hashim, Y. M., Spitzer, D., Vangveravong, S., Hornick, M. C., Garg, G., Hornick, J. R., Goedegebuure, P. S., Mach, R. H., & Hawkins, W. G. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.03.005 · Cited by 44
Amato, R. J., Shetty, A., Lu, Y., Ellis, R., & Low, P. S. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182917f59 · Cited by 42
Self-citationTomasi, G., Kenny, L. M., Mauri, F. A., Turkheimer, F., & Aboagye, E. O. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1907-9 · Cited by 41
A cell-based single-stranded DNA aptamer specifically targets gastric cancer
Zhang, X., Zhang, J., Ma, Y., Pei, X., Liu, Q., Lü, B., Li, J., Wang, J., & Liu, J. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.10.006 · Cited by 41
Shen, J., Chelvam, V., Cresswell, G. M., & Low, P. S. (2013) · Molecular Pharmaceutics · doi:10.1021/mp3006962 · Cited by 40
Self-citationHouri, N., Huang, K.-C., & Nalbantoglu, J. N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073296 · Cited by 40
Kumar, P., Shustov, G. V., Liang, H., Khlebnikov, V., Zheng, W., Yang, X., Cheeseman, C. I., & Wiebe, L. I. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2017336 · Cited by 39
Guillemard, V., Nedev, H. N., Berezov, A., Murali, R., & Saragovi, H. U. (2005) · DNA and Cell Biology · doi:10.1089/dna.2005.24.351 · Cited by 34
Synthesis and Biological Characterization of Protease-Activated Prodrugs of Doxazolidine
Barthel, B. L., Rudnicki, D. L., Kirby, T. P., Colvin, S. M., Burkhart, D. J., & Koch, T. H. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300714p · Cited by 34
Lesche, R., Kettschau, G., Gromov, A., Böhnke, N., Borkowski, S., Mönning, U., Hegele‐Hartung, C., Döhr, O., Dinkelborg, L. M., & Graham, K. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2527-3 · Cited by 34
In Vivo Antitumor Activity of Novel Water-Soluble Taxoids
Mikuni, K., Nakanishi, K., Hara, K., Hara, K., Iwatani, W., Amano, T., NAKAMURA, K., Tsuchiya, Y., Okumoto, H., & Mandai, T. (2008) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.31.1155 · Cited by 32
Valckenborgh, E. V., Mincher, D. J., Salvo, A. D., Riet, I. V., Young, L. S., Camp, B. V., & Vanderkerken, K. (2005) · Leukemia · doi:10.1038/sj.leu.2403866 · Cited by 32
Mesteri, I., SCHOPPMANN, S. F., Preusser, M., & Birner, P. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.01.022 · Cited by 30
Orikawa, Y., Kato, H., Seto, K., Kobayashi, N., Yoshinaga, K., Hamano, H., Hori, Y., Meyer, T., & Takei, M. (2010) · Molecular Pain · doi:10.1186/1744-8069-6-72 · Cited by 29
Folate-Linked Drugs for the Treatment of Cancer and Inflammatory Diseases
Yang, J. J. J., Vlashi, E., & Low, P. S. (2011) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-2199-9_9 · Cited by 24
Self-citationTumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling
Little, A. S., Balmanno, K., Sale, M. J., Smith, P. D., & Cook, S. J. (2012) · Biochemical Society Transactions · doi:10.1042/bst20110647 · Cited by 24
Miot-Noirault, É., Reux, B., Débiton, E., Madelmont, J., Chezal, J., Coudert, P., & Weber, V. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9371-0 · Cited by 24
Brentuximab Vedotin in CD30+ Lymphomas
Perini, G. F., & Pro, B. (2013) · Biologics in Therapy · doi:10.1007/s13554-013-0008-7 · Cited by 24
Degradation of BMS-753493, a novel epothilone folate conjugate anticancer agent
Gokhale, M. Y., Thakur, A. B., & Rinaldi, F. A. (2012) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2012.728226 · Cited by 23
Kulkarni, H., Schuchardt, C., & Baum, R. P. (2012) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-27994-2_32 · Cited by 22
Matteo, P. D., Hackl, C., Jedeszko, C., Valentinis, B., Bordignon, C., Traversari, C., Kerbel, R. S., & Gp, R. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.347 · Cited by 19
Screening of a Novel Peptide Targeting the Proteoglycan-Like Region of Human Carbonic Anhydrase IX
Rana, S., Nissen, F., Lindner, T., Altmann, A., Mier, W., Debus, J., Haberkorn, U., & Askoxylakis, V. (2013) · Molecular Imaging · doi:10.2310/7290.2013.00066 · Cited by 19
c-MET overexpression as a prognostic biomarker in colorectal adenocarcinoma.
Abou-Bakr, A. A.-E., & Elbasmi, A. (2013) · PubMed · Cited by 18
Chan, S., Leu, W., Hsu, L., Chang, H., Hwang, T., Chen, I., Chen, C., & Guh, J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.09.021 · Cited by 17
Glucagonlike Peptide-1 Receptor: An Example of Translational Research in Insulinomas: A Review
Christ, E., Wild, D., & Reubi, J. C. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.09.003 · Cited by 16
Polypeptide conjugates of d-penicillamine and idarubicin for anticancer therapy
Wadhwa, S., & Mumper, R. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.027 · Cited by 13
Tumor biology and cancer therapy – an evolving relationship
Seufferlein, T. T. W., Ahn, J., Krndija, D., Lother, U., Adler, G., & von Wichert, G. (2009) · Cell Communication and Signaling · doi:10.1186/1478-811x-7-19 · Cited by 12
How to target apoptosis signaling pathways for the treatment of pediatric cancers
Fulda, S. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00022 · Cited by 10
Lin, N., Zheng, W., Li, L., Liu, H., Wang, T., Wang, P., & Ma, X. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0282-9 · Cited by 9
Brabez, N., Nguyen, K. L., Saunders, K., Lacy, R., Xu, L., Gillies, R. J., Lynch, R. M., Chassaing, G., Lavielle, S., & Hruby, V. J. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.02.022 · Cited by 7
Cited by
Recent Strategies to Develop Innovative Photosensitizers for Enhanced Photodynamic Therapy
Pham, T. C., Nguyen, V.-N., Choi, Y., Lee, S., & Yoon, J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00381 · Cited by 1,813
Fluorescent chemical probes for accurate tumor diagnosis and targeting therapy
Gao, M., Yu, F., Lv, C., Choo, J., & Chen, L. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00908e · Cited by 827
The expanding role of prodrugs in contemporary drug design and development
Rautio, J., Meanwell, N. A., Di, L., & Hageman, M. J. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.46 · Cited by 767
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 605
Self-citationAdvances in targeting the folate receptor in the treatment/imaging of cancers
Fernández, M., Javaid, F., & Chudasama, V. (2018) · Chemical Science · doi:10.1039/c7sc04004k · Cited by 539
Metadata
- Authors
- Srinivasarao, M., Galliford, C. V., & Low, P. S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-02-20
- Volume
- 14
- Issue
- 3
- Pages
- 203-219
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2041914114
- Cited by
- 671
- References
- 182
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.